Literature DB >> 11779494

DNA ligase IV mutations identified in patients exhibiting developmental delay and immunodeficiency.

M O'Driscoll1, K M Cerosaletti, P M Girard, Y Dai, M Stumm, B Kysela, B Hirsch, A Gennery, S E Palmer, J Seidel, R A Gatti, R Varon, M A Oettinger, H Neitzel, P A Jeggo, P Concannon.   

Abstract

DNA ligase IV functions in DNA nonhomologous end-joining and V(D)J recombination. Four patients with features including immunodeficiency and developmental and growth delay were found to have mutations in the gene encoding DNA ligase IV (LIG4). Their clinical phenotype closely resembles the DNA damage response disorder, Nijmegen breakage syndrome (NBS). Some of the mutations identified in the patients directly disrupt the ligase domain while others impair the interaction between DNA ligase IV and Xrcc-4. Cell lines from the patients show pronounced radiosensitivity. Unlike NBS cell lines, they show normal cell cycle checkpoint responses but impaired DNA double-strand break rejoining. An unexpected V(D)J recombination phenotype is observed involving a small decrease in rejoining frequency coupled with elevated imprecision at signal junctions.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11779494     DOI: 10.1016/s1097-2765(01)00408-7

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  167 in total

Review 1.  Molecular aspects of primary immunodeficiencies: lessons from cytokine and other signaling pathways.

Authors:  Fabio Candotti; Luigi Notarangelo; Roberta Visconti; John O'Shea
Journal:  J Clin Invest       Date:  2002-05       Impact factor: 14.808

2.  A single amino acid substitution in DNA-PKcs explains the novel phenotype of the CHO mutant, XR-C2.

Authors:  Timothy Woods; Wei Wang; Erin Convery; Abdellatif Errami; Malgorzata Z Zdzienicka; Katheryn Meek
Journal:  Nucleic Acids Res       Date:  2002-12-01       Impact factor: 16.971

Review 3.  Unravelling the web of DNA repair disorders.

Authors:  A R Gennery; M O'Driscoll
Journal:  Clin Exp Immunol       Date:  2003-12       Impact factor: 4.330

4.  Molecular cross-talk among chromosome fragility syndromes.

Authors:  Jordi Surrallés; Stephen P Jackson; Maria Jasin; Michael B Kastan; Stephen C West; Hans Joenje
Journal:  Genes Dev       Date:  2004-06-15       Impact factor: 11.361

Review 5.  Genetic and epigenetic features in radiation sensitivity. Part II: implications for clinical practice and radiation protection.

Authors:  Michel H Bourguignon; Pablo A Gisone; Maria R Perez; Severino Michelin; Diana Dubner; Marina Di Giorgio; Edgardo D Carosella
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-03       Impact factor: 9.236

6.  A DNA-PKcs mutation in a radiosensitive T-B- SCID patient inhibits Artemis activation and nonhomologous end-joining.

Authors:  Mirjam van der Burg; Hanna Ijspeert; Nicole S Verkaik; Tuba Turul; Wouter W Wiegant; Keiko Morotomi-Yano; Pierre-Olivier Mari; Ilhan Tezcan; David J Chen; Malgorzata Z Zdzienicka; Jacques J M van Dongen; Dik C van Gent
Journal:  J Clin Invest       Date:  2008-12-15       Impact factor: 14.808

7.  Protein oxidation and DNA repair inhibition by 6-thioguanine and UVA radiation.

Authors:  Quentin Gueranger; Feng Li; Matthew Peacock; Annabel Larnicol-Fery; Reto Brem; Peter Macpherson; Jean-Marc Egly; Peter Karran
Journal:  J Invest Dermatol       Date:  2013-11-27       Impact factor: 8.551

Review 8.  Mouse models of DNA double-strand break repair and neurological disease.

Authors:  Pierre-Olivier Frappart; Peter J McKinnon
Journal:  DNA Repair (Amst)       Date:  2008-05-23

9.  Forkhead-associated domain of yeast Xrs2, a homolog of human Nbs1, promotes nonhomologous end joining through interaction with a ligase IV partner protein, Lif1.

Authors:  Kenichiro Matsuzaki; Akira Shinohara; Miki Shinohara
Journal:  Genetics       Date:  2008-05-05       Impact factor: 4.562

Review 10.  DNA repair deficiency and neurological disease.

Authors:  Peter J McKinnon
Journal:  Nat Rev Neurosci       Date:  2009-01-15       Impact factor: 34.870

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.